Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$5.93
+0.05 (+0.85%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $64.7M · quality 35.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
10/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.1B
P/E
N/A
•EV/EBITDA
33.7x
↑ROE
-6.7%
↓Gross Margin
62.1%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-15.9%
FCF CAGR
-34.1%
FCF margin
10.4%
FCF / Net income
-0.19x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $623.6M · net income $-347.2M · FCF $64.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $623.6M | $623.6M | $660.4M | $1.02B | $1.05B |
| Net Income | $-347.2M | $-347.2M | $-74.1M | $416.7M | $234.4M |
| EBITDA | $164.1M | $164.1M | $196.7M | $610.3M | $373.3M |
| EPS | -0.34 | -0.34 | -0.07 | 0.41 | 0.23 |
| Gross Margin | 62.1% | 62.1% | 68.0% | 81.6% | 85.1% |
| Operating Margin | -0.4% | -0.4% | 6.6% | 24.6% | 17.3% |
| Net Margin | -55.7% | -55.7% | -11.2% | 40.9% | 22.3% |
| Balance Sheet | |||||
| Current Ratio | 3.38 | 3.38 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $64.7M | $64.7M | $-121.9M | $241.8M | $226.3M |
| Returns | |||||
| ROE | -6.7% | -6.7% | -1.3% | 7.2% | 4.3% |
| Valuation | |||||
| P/E | — | — | — | 24.10 | 36.48 |
| EV/EBITDA | 33.73 | 33.73 | 38.30 | 15.33 | 21.31 |
| P/B | 1.17 | 1.17 | 1.43 | 1.73 | 1.56 |
| Growth & Yield | |||||
| Revenue Growth | -5.6% | -5.6% | -35.1% | -3.0% | — |
| EPS Growth | -385.7% | -385.7% | -117.1% | 78.3% | — |
| Dividend Yield | 0.3% | 0.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-10.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.07 → -0.34
Residual
-11.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.